ASCO 2019: New treatment of metastatic cutaneous squamous cell carcinoma

This phase 2 study of cemiplimab (Libtayo), a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma demonstrates substantial antitumor activity and increasing duration of response with cemiplimab 3 mg/kg Q2W in pts with mCSCC. Cemiplimab as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation”